These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 21224028)

  • 41. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood pressure in diabetic nephropathy--current controversies.
    Ritz E; Rychlík I; Schömig M; Wagner J
    J Intern Med; 2001 Mar; 249(3):215-23. PubMed ID: 11293432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Present and future in the treatment of diabetic kidney disease.
    Quiroga B; Arroyo D; de Arriba G
    J Diabetes Res; 2015; 2015():801348. PubMed ID: 25945357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy.
    Ruilope LM
    J Hypertens Suppl; 1995 Aug; 13(2):S91-3. PubMed ID: 8576796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Renin-angiotensin system in diabetic nephropathy].
    Luño J
    Nefrologia; 2005; 25 Suppl 2():73-81. PubMed ID: 16050407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA
    Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role of ramipril in the therapy of diabetic nephropathy].
    Dézsi CA
    Orv Hetil; 2014 Feb; 155(7):263-9. PubMed ID: 24509355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH; Fu P
    Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E; Rychlík I; Miltenberger-Miltenyi G
    J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 55. Appropriate drug therapy for improving outcomes in diabetic nephropathy.
    Toto RD
    Curr Diab Rep; 2002 Dec; 2(6):545-52. PubMed ID: 12643162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
    Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
    Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.